<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090516</url>
  </required_header>
  <id_info>
    <org_study_id>Ginkgo biloba</org_study_id>
    <nct_id>NCT03090516</nct_id>
  </id_info>
  <brief_title>Clinical Study on Improving the Cognitive Function of Patients With Mild to Moderate Alzheimer's Disease by Using Ginkgo Biloba Dispersible Tablets</brief_title>
  <official_title>Clinical Study on Improving the Cognitive Function of Patients With Mild to Moderate Alzheimer's Disease by Using Ginkgo Biloba Dispersible Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project explores Ginkgo biloba ester dispersible tablets influence on cognitive function
      in patients with mild-to-moderate elderly, to observe the effects of different intervention
      time on cognitive function, for alzheimer's patients in drug rehabilitation treatment
      provides an effective solution.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2016</start_date>
  <completion_date type="Anticipated">March 10, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scales to assess</measure>
    <time_frame>change from baseline MMSE at 12weeks</time_frame>
    <description>MMSE（Mini-mental State Examinatlon）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electroencephalography P300</measure>
    <time_frame>change from baseline at 12weeks</time_frame>
    <description>participants distinguish two voice and count them at the same time.we record their electroencephalography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>liver function (blood)</measure>
    <time_frame>change from baseline at 12weeks</time_frame>
    <description>liver function（aspartate transaminase，Alanine aminotransferase，low density lipoprotein，Serum total cholesterol，Triglyceride）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>1.5T MRI changes</measure>
    <time_frame>changes before and after 12weeks</time_frame>
    <description>Magnetic Resonance Imaging</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Alzheimer disease assessment scale (ADAS-cog)</measure>
    <time_frame>change from baseline ADAS-cog at 12 weeks</time_frame>
    <description>ADAS-cog</description>
  </primary_outcome>
  <primary_outcome>
    <measure>activities of daily living scale (ADL)</measure>
    <time_frame>change from baseline ADL at 12 weeks</time_frame>
    <description>ADL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in neuropsychiatrc interventory (NPI)</measure>
    <time_frame>change from baseline NPI at 12weeks</time_frame>
    <description>NPI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in geriatric depression scale (GDS)</measure>
    <time_frame>change from baseline GDS at 12 weeks</time_frame>
    <description>GDS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>renal function</measure>
    <time_frame>change from baseline at 12weeks</time_frame>
    <description>blood urea nitrogen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>change from baseline at 12weeks</time_frame>
    <description>Electrocardiograph</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Alzheimer's</condition>
  <arm_group>
    <arm_group_label>Arm A ：Donepezil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A：People are randomly divided into three groups according to the educational conditiono，gender and age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B ：Donepezil and Ginkgo biloba dispersible tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B：People are randomly divided into three groups according to the educational conditiono，gender and age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C：Ginkgo biloba dispersible tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C：People are randomly divided into three groups according to the educational conditiono，gender and age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginkgo biloba dispersible tablets</intervention_name>
    <description>Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.</description>
    <arm_group_label>Arm C：Ginkgo biloba dispersible tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil</intervention_name>
    <description>Arm A：Aricept 5mg/day</description>
    <arm_group_label>Arm A ：Donepezil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginkgo biloba dispersible tablets and Donepezil</intervention_name>
    <description>Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.</description>
    <arm_group_label>Arm B ：Donepezil and Ginkgo biloba dispersible tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. All patients were diagnosed with dementia caused by AD in 2011, the latest diagnostic
             criteria for Alzheimer's disease (NIA-AA), according to the patient's clinical and
             cranial imaging findings

          2. Improved Hachinski ischemic scale score &lt;4

          3. All patients underwent head CT and / or MRI examinations and laboratory tests to rule
             out other causes of dementia

          4. MMSE(High school≤24,Primary school≤20;illiteracy≤17)

          5. CDR 1-2

          6. The subjects and nurses signed informed consent, and the nursing staff were able to
             take responsibility for the supervision of the participants

          7. The subjects were stable

          8. Cooperate, willing to complete all parts of the research, and have the ability to
             complete the study alone or with the help of the nursing staff

          9. To cooperate with the study, do not live alone, such as living alone should keep in
             touch with the nurse every day.

        Exclusion Criteria:

          1. Heart lung kidney disease, may interfere to evaluate the efficacy and safety of
             patients at risk or special disease,for example:Congestive heart failure et al.

          2. According to NINDS-AIREN standard (Roman GC et al 1993) is currently diagnosed as
             possible vascular dementia

          3. Improved Hachinski ischemic scale score（MHIS）≥4

          4. Diagnosis of severe depression, schizophrenia, and other major neurodegenerative
             disorders, according to the DSM-IV axis

          5. Neurological or other medical disorders that affect the function of the central
             nervous system,like Moderate anemia,Vitamin B12 or folic acid deficiency, et al. Not
             with the cognitive function examination (including blindness, deafness, severe
             language disorders).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ting Wu</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Wu, professor</last_name>
      <phone>18851122018</phone>
      <email>wuting80000@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Wanrong Zhang, master</last_name>
      <phone>15851875395</phone>
      <email>zwr10010533@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2017</study_first_submitted>
  <study_first_submitted_qc>March 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>March 23, 2017</last_update_submitted>
  <last_update_submitted_qc>March 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Ting Wu</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Ginkgo biloba dispersible tablets</keyword>
  <keyword>Alzheimer's</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

